The "4th Beijing Clinical Mass Spectrometry Forum" and "Expert Consensus on Androgen Mass Spectrometry Detection in Polycystic Ovarian Syndrome" Press Conference will be successfully held on April 13-15, 2023 at the Crowne Plaza Beijing U-Town. The forum was co-hosted by the Beijing-Tianjin-Hebei Women's and Children's Health Specialty Alliance and the Beijing Obstetrics and Gynecology Hospital Affiliated to Capital Medical University, and undertaken by [Antepedia (Beijing) Technology Development Co., Ltd.].
There are large individual differences in androgen levels in PCOS (polycystic ovary syndrome) patients. LC-MS/MS can efficiently evaluate hyperandrogenism due to its advantages of high sensitivity, specificity and multi-target detection, and provide more accurate laboratory basis for clinical diagnosis. It is believed that with the joint efforts of many parties, more and more clinical laboratories will use LC-MS/MS to accurately measure the androgen levels of PCOS patients, so as to provide better reference for clinical diagnosis and treatment, benefit the majority of female patients, and contribute to the new era of my country's new era. The effective advancement of the period's childbirth policy provides assistance. This press conference on the expert consensus on androgen mass spectrometry detection in polycystic ovary syndrome will greatly promote the application of mass spectrometry detection in the accurate diagnosis and treatment of PCOS.
Shanghai Baiqu Metabolomics Technology Research Center is honored to be invited as the author of this expert consensus, and Ms. Huang Yingyu represented Shanghai Baiqu and Beijing Obstetrics and Gynecology Hospital affiliated to Capital Medical University, a total of 5 experts participated in the expert consensus The drafting and formulation of this expert consensus reflects the technical advantages of Shanghai Baiqu in the field of clinical mass spectrometry. Shanghai Baiqu has always regarded technological innovation and development as the core competitiveness of the enterprise. The expert consensus that participated in the formulation this time is to continuously promote the use of LC-MS/MS technology in medical institutions for androgen detection through extensive cooperation and exchanges with experts from various parties, and to provide precise medical services for PCOS patients.
Press conference pictures: (the fourth from the right is Ms. Huang Yingyu from Shanghai Baiqu Metabolomics Technology Research Center)
This time, Baiqu Biotech brought Qlab3 MD-mass spectrometry automatic sample pretreatment system, catecholamine and its metabolite detection scheme, various steroid hormone determination kits, discovery metabolomics and other products to the conference and set up a booth. Diversified products that meet the all-round demands of clinical and scientific research have attracted a large number of participating experts to stop at the booth of Baiqu for exchanges and cooperation.
Participating in the expert consensus conference on mass spectrometry detection of male hormones in polycystic ovary syndrome, Baiqu focused on displaying solutions in the field of detection of various steroid hormones. In order to better serve the clinic, according to the disease detection needs of different departments, Baiqu has developed two kits, 19 steroid hormones (SPE) and 6 steroid hormones (LLE). These two products can accurately measure the androgen level of PCOS patients, which can better provide reference for clinical diagnosis and treatment. Among them, 6 steroid hormone LLE methods can better meet the clinical detection needs of polycystic ovary syndrome, and 19 steroid hormone SPE methods are useful in the diagnosis and differential diagnosis of PCOS, and the diagnosis and classification of congenital adrenal hyperplasia (CAH). Type, and secondary hypertension have greater advantages.
The following is the text of the expert consensus
